199 related articles for article (PubMed ID: 12739985)
21. Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction.
Christersson C; Oldgren J; Bylock A; Wallentin L; Siegbahn A
J Thromb Haemost; 2005 Oct; 3(10):2245-53. PubMed ID: 16194202
[TBL] [Abstract][Full Text] [Related]
22. The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol.
Sarich TC; Johansson S; Schützer KM; Wall U; Kessler E; Teng R; Eriksson UG
J Clin Pharmacol; 2004 Apr; 44(4):388-93. PubMed ID: 15051746
[TBL] [Abstract][Full Text] [Related]
23. A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor.
Teng R; Sarich TC; Eriksson UG; Hamer JE; Gillette S; Schützer KM; Carlson GF; Kowey PR
J Clin Pharmacol; 2004 Sep; 44(9):1063-71. PubMed ID: 15317834
[TBL] [Abstract][Full Text] [Related]
24. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.
Gustafsson D; Nyström J; Carlsson S; Bredberg U; Eriksson U; Gyzander E; Elg M; Antonsson T; Hoffmann K; Ungell A; Sörensen H; Någård S; Abrahamsson A; Bylund R
Thromb Res; 2001 Feb; 101(3):171-81. PubMed ID: 11228340
[TBL] [Abstract][Full Text] [Related]
25. Oral direct thrombin inhibitors in clinical development.
Gustafsson D
J Intern Med; 2003 Oct; 254(4):322-34. PubMed ID: 12974871
[TBL] [Abstract][Full Text] [Related]
26. Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects.
Boström SL; Hansson GF; Kjaer M; Sarich TC
Blood Coagul Fibrinolysis; 2003 Jul; 14(5):457-62. PubMed ID: 12851531
[TBL] [Abstract][Full Text] [Related]
27. Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol.
Wolzt M; Sarich TS; Eriksson UG
Semin Vasc Med; 2005 Aug; 5(3):254-8. PubMed ID: 16123912
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men.
Johansson S; Wåhlander K; Larson G; Ohlsson L; Larsson M; Eriksson UG
Blood Coagul Fibrinolysis; 2003 Oct; 14(7):677-84. PubMed ID: 14517494
[TBL] [Abstract][Full Text] [Related]
29. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma.
Boström SL; Hansson GF; Sarich TC; Wolzt M
Thromb Res; 2004; 113(1):85-91. PubMed ID: 15081569
[TBL] [Abstract][Full Text] [Related]
30. No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran.
Sarich TC; Schützer KM; Dorani H; Wall U; Kalies I; Ohlsson L; Eriksson UG
J Clin Pharmacol; 2004 Aug; 44(8):928-34. PubMed ID: 15286097
[TBL] [Abstract][Full Text] [Related]
31. No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers.
Sarich TC; Schützer KM; Wollbratt M; Wall U; Kessler E; Eriksson UG
J Clin Pharmacol; 2004 Aug; 44(8):935-41. PubMed ID: 15286098
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis.
Cullberg M; Eriksson UG; Wåhlander K; Eriksson H; Schulman S; Karlsson MO
Clin Pharmacol Ther; 2005 Apr; 77(4):279-90. PubMed ID: 15903126
[TBL] [Abstract][Full Text] [Related]
33. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
Evans HC; Perry CM; Faulds D
Drugs; 2004; 64(6):649-78. PubMed ID: 15018597
[TBL] [Abstract][Full Text] [Related]
34. The direct thrombin inhibitor melagatran/ximelagatran.
Brighton TA
Med J Aust; 2004 Oct; 181(8):432-7. PubMed ID: 15487959
[TBL] [Abstract][Full Text] [Related]
35. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.
Sarich TC; Wolzt M; Eriksson UG; Mattsson C; Schmidt A; Elg S; Andersson M; Wollbratt M; Fager G; Gustafsson D
J Am Coll Cardiol; 2003 Feb; 41(4):557-64. PubMed ID: 12598065
[TBL] [Abstract][Full Text] [Related]
36. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination.
Koestenberger M; Gallistl S; Cvirn G; Baier K; Leschnik B; Muntean W
Thromb Res; 2005; 115(1-2):135-42. PubMed ID: 15567465
[TBL] [Abstract][Full Text] [Related]
37. Ximelagatran--a promising new drug in thromboembolic disorders.
Petersen P
Curr Pharm Des; 2005; 11(4):527-38. PubMed ID: 15725069
[TBL] [Abstract][Full Text] [Related]
38. [The oral direct thrombin inhibitor Ximelagatran Prophylaxis of venous thromboembolism in hip and knee replacement].
Mouret P
Hamostaseologie; 2002 Aug; 22(3):21-4. PubMed ID: 12215757
[TBL] [Abstract][Full Text] [Related]
39. Bioequivalence of ximelagatran, an oral direct thrombin inhibitor, as whole or crushed tablets or dissolved formulation.
Schützer KM; Wall U; Lönnerstedt C; Ohlsson L; Teng R; Sarich TC; Eriksson UG
Curr Med Res Opin; 2004 Mar; 20(3):325-31. PubMed ID: 15025841
[TBL] [Abstract][Full Text] [Related]
40. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug.
Clement B; Lopian K
Drug Metab Dispos; 2003 May; 31(5):645-51. PubMed ID: 12695354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
